Dr. Greg Verdine joins the show at 7:04. He's the co-founder, president, and CEO of LifeMine Therapeutics, and the Erving Professor of Chemistry at Harvard in the Departments of Stem Cell and Regenerative Biology and Chemistry and Chemical Biology. He's founded multiple drug discovery companies that have gone public or been acquired. We're going to talk about a new pancreatic cancer drug that's stunning researchers in early trials — a disease that's deeply personal to me (my father-in-law died six weeks after diagnosis). I want to ask him why pancreatic cancer has been so impervious to treatment, what KRAS is and why the physical nature of the cell makes it such a difficult target, what's special about this new drug, whether we're talking about extending lives by months or actually curing the disease, and why fungi are such promising sources of new therapeutics.
New pancreatic cancer pill could reshape treatment as early trial results stun researchers
New pancreatic cancer drug in high demand. How daraxonrasib works